Edition:
United States

TRACON Pharmaceuticals Inc (TCON.OQ)

TCON.OQ on NASDAQ Stock Exchange Global Market

1.61USD
4:00pm EDT
Change (% chg)

$-0.11 (-6.40%)
Prev Close
$1.72
Open
$1.70
Day's High
$1.70
Day's Low
$1.61
Volume
53,753
Avg. Vol
17,425
52-wk High
$3.55
52-wk Low
$1.61

Chart for

About

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is... (more)

Overall

Beta: 1.87
Market Cap(Mil.): $57.29
Shares Outstanding(Mil.): 29.84
Dividend: --
Yield (%): --

Financials

  TCON.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -1.09 -- --
ROI: -69.86 1.96 12.83
ROE: -86.66 1.12 14.95

BRIEF-Tracon Pharmaceuticals Files For Offering Of Up To 27.4 Mln Shares Of Common Stock By The Selling Stockholders

* TRACON PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 27.4 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS Source text: [https://bit.ly/2KQef7f] Further company coverage:

May 10 2018

BRIEF-TRACON Pharmaceuticals Reports Qtrly Loss Per Share $0.46

* TRACON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Tracon Pharmaceuticals Says Patricia Bitar Notified That Resigning As Co's CFO

* TRACON PHARMACEUTICALS INC - ON APRIL 30, PATRICIA L. BITAR NOTIFIED THAT RESIGNING AS CO'S CFO, EFFECTIVE JUNE 15, 2018- SEC FILING Source text for Eikon: (https://bit.ly/2w9w9yD) Further company coverage:

May 04 2018

Earnings vs. Estimates